- A Chinese multicenter trial found that intravenous alteplase administration up to 24 hours post–stroke onset improved functional outcomes.
- The trial challenged current therapeutic time windows for thrombolytic therapy.
- 40% of alteplase-treated patients achieved minimal or no disability at 90 days compared to 26% in the standard care group.
- Eligibility required computed tomography (CT) perfusion imaging evidence of salvageable brain tissue.
- The findings contrast with existing guidelines, potentially impacting stroke treatment worldwide.
Late-Window Alteplase in Acute Ischemic Stroke
Conexiant
February 19, 2025
